NCT01123356View on ClinicalTrials.gov

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Ofatumumab

"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"

DRUG

Lenalidomide

-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)

Trial Locations (2)

29425

Medical University of South Carolina, Charleston

29605

Greenville Hospital System, Greenville

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Medical University of South Carolina

OTHER